Upgrade to SI Premium - Free Trial

Form SCHEDULE 13G/A Foghorn Therapeutics Filed by: Flynn James E

May 14, 2026 6:21 PM





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: Comprised of (i) 4,394,367 shares of common stock and (ii) 745,156 shares of common stock issuable upon exercise of warrants, which, in each case, are held by Deerfield Partners, L.P., of which Deerfield Mgmt, L.P. is the general partner. The provisions of the warrants beneficially owned by the reporting person restrict the exercise of such securities to the extent that after such exercise the holder, its affiliates and other persons whose beneficial ownership of common stock would be aggregated for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, would beneficially own in excess of 9.99% of the total number of shares of the Issuer then outstanding (the "Ownership Cap"). Accordingly, notwithstanding the number of shares reported, the reporting person disclaims beneficial ownership of the shares of common stock issuable upon exercise of such warrants to the extent that upon such exercise the number of shares beneficially owned by all reporting persons hereunder, in the aggregate, would exceed the Ownership Cap.


SCHEDULE 13G




Comment for Type of Reporting Person: Comprised of (i) 4,394,367 shares of common stock and (ii) 745,156 shares of common stock issuable upon exercise of warrants, which, in each case, are held by Deerfield Partners, L.P., of which Deerfield Management Company, L.P. is the investment advisor. The provisions of the warrants beneficially owned by the reporting person restrict the exercise of such securities to the extent that after such exercise the holder, its affiliates and other persons whose beneficial ownership of common stock would be aggregated for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, would beneficially own in excess of 9.99% of the total number of shares of the Issuer then outstanding (the "Ownership Cap"). Accordingly, notwithstanding the number of shares reported, the reporting person disclaims beneficial ownership of the shares of common stock issuable upon exercise of such warrants to the extent that upon such exercise the number of shares beneficially owned by all reporting persons hereunder, in the aggregate, would exceed the Ownership Cap.


SCHEDULE 13G




Comment for Type of Reporting Person: Comprised of (i) 4,394,367 shares of common stock and (ii) 745,156 shares of common stock issuable upon exercise of warrants. The provisions of the warrants beneficially owned by the reporting person restrict the exercise of such securities to the extent that after such exercise the holder, its affiliates and other persons whose beneficial ownership of common stock would be aggregated for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, would beneficially own in excess of 9.99% of the total number of shares of the Issuer then outstanding (the "Ownership Cap"). Accordingly, notwithstanding the number of shares reported, the reporting person disclaims beneficial ownership of the shares of common stock issuable upon exercise of such warrants to the extent that upon such exercise the number of shares beneficially owned by all reporting persons hereunder, in the aggregate, would exceed the Ownership Cap.


SCHEDULE 13G




Comment for Type of Reporting Person: Comprised of (i) 4,394,367 shares of common stock and (ii) 745,156 shares of common stock issuable upon exercise of warrants, which, in each case, are held by Deerfield Partners, L.P. The provisions of the warrants beneficially owned by the reporting person restrict the exercise of such securities to the extent that after such exercise the holder, its affiliates and other persons whose beneficial ownership of common stock would be aggregated for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, would beneficially own in excess of 9.99% of the total number of shares of the Issuer then outstanding (the "Ownership Cap"). Accordingly, notwithstanding the number of shares reported, the reporting person disclaims beneficial ownership of the shares of common stock issuable upon exercise of such warrants to the extent that upon such exercise the number of shares beneficially owned by all reporting persons hereunder, in the aggregate, would exceed the Ownership Cap.


SCHEDULE 13G



Deerfield Mgmt, L.P.
Signature:/s/ Jonathan Isler
Name/Title:Jonathan Isler, Attorney-In-Fact
Date:05/14/2026
Deerfield Management Company, L.P.
Signature:/s/ Jonathan Isler
Name/Title:Jonathan Isler, Attorney-In-Fact
Date:05/14/2026
Deerfield Partners, L.P.
Signature:/s/ Jonathan Isler
Name/Title:Jonathan Isler, Attorney-In-Fact
Date:05/14/2026
James E. Flynn
Signature:/s/ Jonathan Isler
Name/Title:Jonathan Isler, Attorney-In-Fact
Date:05/14/2026
Exhibit Information

Exhibit A. Joint Filing Agreement. Exhibit B. Item 8 Statement. Exhibit C. Power of Attorney (1). (1) Power of Attorney previously filed as Exhibit 24 to a Form 3 with regard to BiomX Inc. filed with the Securities and Exchange Commission on March 19, 2024 by Deerfield Private Design Fund V, L.P., Deerfield Healthcare Innovations Fund II, L.P., Deerfield Mgmt V, L.P., Deerfield Mgmt HIF II, L.P., Deerfield Management Company, L.P. and James E. Flynn.

ATTACHMENTS / EXHIBITS

e665477_ex99-a.htm

e665477_ex99-b.htm

Categories

SEC Filings